**Core Concept**
The correct answer involves the treatment of Chronic Myeloid Leukemia (CML), a type of cancer characterized by the proliferation of myeloid cells in the bone marrow. CML is often associated with a chromosomal abnormality known as the Philadelphia chromosome, resulting from a translocation between chromosomes 9 and 22.

**Why the Correct Answer is Right**
The treatment of CML has evolved significantly with the introduction of targeted therapies. Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for CML, as they specifically target the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib, a first-generation TKI, was the first line of treatment and has been widely used. However, newer second-generation TKIs like dasatinib and nilotinib have shown improved efficacy and are now preferred due to their ability to inhibit BCR-ABL with greater potency.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not represent a commonly used treatment for CML. Interferon-alpha was previously used as a treatment option for CML, but it has largely been replaced by TKIs due to their improved efficacy and tolerability.
**Option B:** This option is incorrect because it is not a specific treatment for CML. Corticosteroids are used to treat a variety of conditions, including inflammation and autoimmune disorders, but they are not the primary treatment for CML.
**Option C:** This option is incorrect because it does not accurately represent the current standard of care for CML. Chemotherapy is not typically used as a first-line treatment for CML, as it can be associated with significant toxicity and does not target the underlying molecular abnormality.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that the treatment of CML has evolved significantly, and TKIs have become the mainstay of treatment. The choice of TKI should be based on individual patient factors, including comorbidities and response to previous therapies.

**Correct Answer: D. Imatinib (or another second-generation TKI like Dasatinib or Nilotinib)**